Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy
Abstract Background Autoimmune retinopathy (AIR) is a rare but potentially blinding condition that is often underdiagnosed. Common features in AIR presentation include rapidly progressive vision loss with abnormal electrophysiological responses of the retina associated with positive anti-retinal ant...
Main Authors: | Katherine Boudreault, Sally Justus, Jesse D. Sengillo, Kaspar Schuerch, Winston Lee, Thiago Cabral, Stephen H. Tsang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-07-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-017-0680-7 |
Similar Items
-
Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy
by: Gunay Uludag, et al.
Published: (2016-07-01) -
Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial
by: Karen R Armbrust, et al.
Published: (2021-01-01) -
Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
by: Maleki A, et al.
Published: (2017-02-01) -
Paraneoplastic retinopathies
by: Marko Hawlina, et al.
Published: (2005-10-01) -
Non-paraneoplastic autoimmune retinopathy: multimodal testing characteristics of 13 cases
by: Saira Khanna, et al.
Published: (2019-02-01)